FFA
SMMT icon

Farther Finance Advisors’s Summit Therapeutics SMMT Stock Holding History

Farther Finance Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$496K Buy
29,308
+4,007
+16% +$59.9K ﹤0.01% 1600
2026
Q2 		$369K Sell
25,301
-25,015
-50% -$444K ﹤0.01% 1784
2026
Q1 		$952K Sell
50,316
-6,966
-12% -$113K 0.01% 994
2025
Q4 		$1M Buy
57,282
+2,046
+4% +$38.5K 0.01% 888
2025
Q3 		$1.14M Buy
55,236
+54,676
+9,764% +$1.33M 0.02% 659
2025
Q2 		$11.9K Sell
560
-94
-14% -$2.14K ﹤0.01% 2986
2025
Q1 		$12.3K Buy
654
+642
+5,350% +$12.9K ﹤0.01% 2641
2024
Q4 		$214 Buy
+12
New +$233 ﹤0.01% 3647

Other funds holding SMMT

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
MHR
Matthew Hamilton Rosenberg $558M AUM 12.28% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Farther Finance Advisors's SMMT Position: Q3 2026 in Review

Farther Finance Advisors increased its Summit Therapeutics (SMMT) stake by 16% in Q3 2026, buying an estimated $59.9K and bringing the position to 29,308 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Farther Finance Advisors first reported a position in SMMT in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.14M in Q3 2025. 10 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Farther Finance Advisors held 29,308 shares of Summit Therapeutics worth $496K as of Q3 2026.
  • Farther Finance Advisors bought 4,007 Summit Therapeutics shares in Q3 2026, an estimated $59.9K.
  • Summit Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #1600 holding.
  • Farther Finance Advisors first reported a position in Summit Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Farther Finance Advisors's Summit Therapeutics position peaked at $1.14M in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.